Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328953 | 0.93 | MGLL (0.40) | MGLLPTGDR2KDRTMEM97SIGMAR1 | |
| SCHEMBL13249802 | 0.91 | KDR (0.45) | PTGDR2KDRTMEM97SIGMAR1DHFR | |
| SCHEMBL13249803 | 0.87 | MGLL (0.56) | MGLL | |
| SCHEMBL13249786 | 0.86 | TSHR (0.45) | ALDH1A1HSD17B10 | |
| SCHEMBL13249950 | 0.85 | PARP1 (0.39) | PTGDR2KDRTMEM97SIGMAR1DHFR | |
| SCHEMBL13328919 | 0.84 | KDR (0.47) | PTGDR2KDRTMEM97SIGMAR1DHFR | |
| SCHEMBL13249779 | 0.83 | CCR2 (0.44) | SIGMAR1ALDH1A1 | |
| SCHEMBL13249798 | 0.82 | PPARG (0.41) | ALDH1A1HSD17B10 | |
| SCHEMBL13249789 | 0.82 | PPARG (0.42) | PTGDR2ALDH1A1 | |
| SCHEMBL13249809 | 0.82 | TP53 (0.48) | PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | MGLL 882/4885PTGDR2 73/4885KDR 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.